Catalá-López Ferrán, Hutton Brian, Driver Jane A, Page Matthew J, Ridao Manuel, Valderas José M, Alonso-Arroyo Adolfo, Forés-Martos Jaume, Martínez Salvador, Gènova-Maleras Ricard, Macías-Saint-Gerons Diego, Crespo-Facorro Benedicto, Vieta Eduard, Valencia Alfonso, Tabarés-Seisdedos Rafael
Department of Medicine, University of Valencia/INCLIVA Health Research Institute and CIBERSAM, Valencia, Spain.
Fundación Instituto de Investigación en Servicios de Salud, Valencia, Spain.
Syst Rev. 2017 Apr 4;6(1):69. doi: 10.1186/s13643-017-0466-y.
The objective of this study will be to synthesize the epidemiological evidence and evaluate the validity of the associations between central nervous system disorders and the risk of developing or dying from cancer.
METHODS/DESIGN: We will perform an umbrella review of systematic reviews and conduct updated meta-analyses of observational studies (cohort and case-control) investigating the association between central nervous system disorders and the risk of developing or dying from any cancer or specific types of cancer. Searches involving PubMed/MEDLINE, EMBASE, SCOPUS and Web of Science will be used to identify systematic reviews and meta-analyses of observational studies. In addition, online databases will be checked for observational studies published outside the time frames of previous reviews. Eligible central nervous system disorders will be Alzheimer's disease, anorexia nervosa, amyotrophic lateral sclerosis, autism spectrum disorders, bipolar disorder, depression, Down's syndrome, epilepsy, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia. The primary outcomes will be cancer incidence and cancer mortality in association with a central nervous system disorder. Secondary outcome measures will be site-specific cancer incidence and mortality, respectively. Two reviewers will independently screen references identified by the literature search, as well as potentially relevant full-text articles. Data will be abstracted, and study quality/risk of bias will be appraised by two reviewers independently. Conflicts at all levels of screening and abstraction will be resolved through discussion. Random-effects meta-analyses of primary observational studies will be conducted where appropriate. Parameters for exploring statistical heterogeneity are pre-specified. The World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) criteria and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used for determining the quality of evidence for cancer outcomes.
Our study will establish the extent of the epidemiological evidence underlying the associations between central nervous system disorders and cancer and will provide a rigorous and updated synthesis of a range of important site-specific cancer outcomes.
PROSPERO CRD42016052762.
本研究的目的是综合流行病学证据,并评估中枢神经系统疾病与患癌风险或癌症死亡风险之间关联的有效性。
方法/设计:我们将对系统评价进行伞状综述,并对观察性研究(队列研究和病例对照研究)进行更新的荟萃分析,以调查中枢神经系统疾病与任何癌症或特定类型癌症的发生风险或死亡风险之间的关联。将使用涉及PubMed/MEDLINE、EMBASE、SCOPUS和Web of Science的检索来识别观察性研究的系统评价和荟萃分析。此外,将检查在线数据库,以查找在前瞻性综述时间范围之外发表的观察性研究。符合条件的中枢神经系统疾病包括阿尔茨海默病、神经性厌食症、肌萎缩侧索硬化症、自闭症谱系障碍、双相情感障碍、抑郁症、唐氏综合征、癫痫、亨廷顿舞蹈病、多发性硬化症、帕金森病和精神分裂症。主要结局将是与中枢神经系统疾病相关的癌症发病率和癌症死亡率。次要结局指标将分别是特定部位的癌症发病率和死亡率。两名审阅者将独立筛选文献检索中识别出的参考文献以及潜在相关的全文文章。将提取数据,两名审阅者将独立评估研究质量/偏倚风险。在所有筛选和提取层面的冲突将通过讨论解决。将在适当情况下对主要观察性研究进行随机效应荟萃分析。探索统计异质性的参数已预先设定。世界癌症研究基金会(WCRF)/美国癌症研究学会(AICR)标准以及推荐分级评估、制定和评价(GRADE)方法将用于确定癌症结局证据的质量。
我们的研究将确定中枢神经系统疾病与癌症之间关联的流行病学证据程度,并将对一系列重要的特定部位癌症结局进行严格且更新的综合分析。
PROSPERO CRD42016052762